The Amazing Times on MSN3d
Five Common Medications That May Increase Your Risk of Dementia
Dementia, a progressive disorder that impacts memory and independence, affects millions globally. While many are aware of ...
New dementia tool predicts when symptoms will start: ‘Would you want to know?’
Nearly 7 million Americans have been diagnosed with dementia, which slowly erodes memory, thinking skills and the ability to ...
Irish Examiner on MSN10d
Breakthrough drugs herald ‘new era’ in battle against dementia, experts predict
Medical advances make pills to treat Alzheimer’s disease viable, though challenges remain in sharing gains globally ...
studyfinds1d
Familiar songs reduce dementia patients’ anxiety, trigger lost memories
Discover the power of music therapy for dementia. Learn how music can reduce distress and improve well-being in institutional ...
Your Good Health: Long-term use of high-dose gabapentin worries patient
The evidence of gabapentin and dementia is mixed, with two studies looking at hundreds of thousands of people and coming to ...
Common sleep medication may prevent brain from clearing 'waste'
In a mouse study, researchers found that zolpidem (Ambien), a common sleep aid, could prevent the brain from effectively ...
Benzinga.com4d
FDA To Review Under the Skin Weekly Autoinjector For Biogen/Eisai's Alzheimer's Drug Leqembi
Leqembi's subcutaneous dosing allows Alzheimer's patients to administer weekly treatment at home in 15 seconds ... s disease ...
New criteria developed for appropriate use of cognitive impairment imaging tools
Appropriate use criteria (AUC) for the use of amyloid and tau positron emission tomography (PET) have been issued by the ...
Monthly Prescribing Reference1d
Lecanemab SC Formulation Under Review for Early Alzheimer Disease
The Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for subcutaneous (SC) maintenance dosing of lecanemab-irmb for the treatment of Alzheimer disease (AD) in ...
China Medical System （00867）Obtained New Drug ZUNVEYL for the Treatment of Mild-to-Moderate Dementia of the Alzheimer’s Type
As the second oral therapy approved by the U.S. Food and Drug Administration (FDA) for the treatment of Alzheimer’s disease during the past decade, ZUNVEYL demonstrates a potentially better safety ...